Human herpesvirus 8-encoded interleukin 6 activates HIV-1 in the U1 monocytic cell line

AIDS ◽  
1999 ◽  
Vol 13 (14) ◽  
pp. 1851-1855 ◽  
Author(s):  
Julia R. Gage ◽  
Elizabeth Crabb Breen ◽  
Angela Echeverri ◽  
Larry Magpantay ◽  
Tadamitsu Kishimoto ◽  
...  
2002 ◽  
Vol 68 (3) ◽  
pp. 404-411 ◽  
Author(s):  
Jian Song ◽  
Takako Ohkura ◽  
Masamichi Sugimoto ◽  
Yasuko Mori ◽  
Reiko Inagi ◽  
...  

2017 ◽  
Vol 23 (4) ◽  
pp. 201-205 ◽  
Author(s):  
Dai Watanabe ◽  
Yudai Yamamoto ◽  
Sachiko Suzuki ◽  
Misa Ashida ◽  
Erina Matsumoto ◽  
...  

2000 ◽  
Vol 61 (3) ◽  
pp. 332-335 ◽  
Author(s):  
Yasuko Mori ◽  
Norihiro Nishimoto ◽  
Mika Ohno ◽  
Reiko Inagi ◽  
Panadda Dhepakson ◽  
...  

AIDS ◽  
2018 ◽  
Vol 32 (3) ◽  
pp. 404-406
Author(s):  
Christopher J.A. Duncan ◽  
Fraser G. Charlton ◽  
Mark Bower ◽  
David A. Price

Author(s):  
Maria Luisa Calabrò ◽  
Paola Gasperini ◽  
Massimo Barbierato ◽  
Lucia Ometto ◽  
Marisa Zanchetta ◽  
...  

2020 ◽  
Vol 94 (19) ◽  
Author(s):  
Qian Li ◽  
Qiwang Xiang ◽  
Daming Chen ◽  
John Nicholas

ABSTRACT Human herpesvirus 8 (HHV-8) viral interleukin-6 (vIL-6) is a cytokine that is poorly secreted and localized largely to the endoplasmic reticulum (ER). It has been implicated, along with other HHV-8 proinflammatory and/or angiogenic viral proteins, in HHV-8-associated Kaposi’s sarcoma, primary effusion lymphoma (PEL), and multicentric Castleman’s disease (MCD), in addition to an MCD-related disorder involving systemic elevation of proinflammatory cytokines, including vIL-6 and human IL-6 (hIL-6). In these diseases, lytic (productive) replication, in addition to viral latency, is believed to play a critical role. Proreplication activity of vIL-6 has been identified experimentally in PEL and endothelial cells, but the relative contributions of different vIL-6 interactions have not been established. Productive interactions of vIL-6 with the IL-6 signal transducer, gp130, can occur within the ER, but vIL-6 also interacts in the ER with a nonsignaling receptor called vitamin K epoxide reductase complex subunit 1 variant 2 (VKORC1v2), calnexin, and VKORC1v2- and calnexin-associated proteins UDP-glucose:glycoprotein glucosyltransferase 1 (UGGT1) and glucosidase II (GlucII). Here, we report the systematic characterization of interaction-altered vIL-6 variants and the lytic phenotypes of recombinant viruses expressing selected variants. Our data identify the critical importance of vIL-6 and its ER-localized activity via gp130 to productive replication in inducible SLK (epithelial) cells, absence of detectable involvement of vIL-6 interactions with VKORC1v2, GlucII, or UGGT1, and the insufficiency and lack of direct contributory effects of extracellular signaling by vIL-6 or hIL-6. These findings, obtained through genetics-based approaches, complement and extend previous analyses of vIL-6 activity. IMPORTANCE Human herpesvirus 8 (HHV-8)-encoded viral interleukin-6 (vIL-6) was the first viral IL-6 homologue to be identified. Experimental and clinical evidence suggests that vIL-6 is important for the onset and/or progression of HHV-8-associated endothelial-cell and B-cell pathologies, including AIDS-associated Kaposi’s sarcoma and multicentric Castleman’s disease. The protein is unusual in its poor secretion from cells and its intracellular activity; it interacts, directly or indirectly, with a number of proteins beyond the IL-6 signal transducer, gp130, and can mediate activities through these interactions in the endoplasmic reticulum. Here, we report the characterization with respect to protein interactions and signal-transducing activity of a panel of vIL-6 variants and utilization of HHV-8 mutant viruses expressing selected variants in phenotypic analyses. Our findings establish the importance of vIL-6 in HHV-8 productive replication and the contributions of individual vIL-6-protein interactions to HHV-8 lytic biology. This work furthers understanding of the biological significance of vIL-6 and its unique intracellular interactions.


2016 ◽  
Vol 136 (1) ◽  
pp. 16-22
Author(s):  
Musa Fares Alzahrani ◽  
Mansoor Radwi ◽  
Heather A. Leitch

Castleman's disease (CD) is a rare lymphoproliferative disorder that is most commonly present in multicentric (MCD) form in association with HIV infection. Interleukin-6 (IL-6) and human herpesvirus-8 (HHV-8) play major roles in MCD pathogenesis. Important treatment options have recently become available, particularly with the introduction of IL-6 and IL-6 receptor inhibitors for the treatment of HIV-negative patients with MCD. Though advances in therapy may improve outcomes in some patients, the prognosis remains guarded, and a stratified approach to the management of MCD is needed.


Sign in / Sign up

Export Citation Format

Share Document